RadarScope: AZN — Analiza Fundamentala

Market Cap

$258.6B

P/E Ratio

24.9

Profit Margin

17.0%

ROE

21.7%

📈 Earnings Report — 2026-07

Ultimul trimestru raportat

EPS Actual

$2.63

▲ 1.9% QoQ▲ 20.6% YoY

EPS Estimat

$2.5

Beat by 5.2%

Revenue Actual

$15.38B

▲ 0.6% QoQ▲ 6.4% YoY

Revenue Estimat

$15.44B

Miss by 0.3%

Istoric Ultimele 4 Trimestre

2026-07

EPS Actual

$2.63

EPS Est.

$2.5

Revenue

$15.38B

Beat/Miss

Beat by 5.2%

2026-04

EPS Actual

$2.58

EPS Est.

$2.57

Revenue

$15.29B

Beat/Miss

Beat by 0.4%

2026-02

EPS Actual

$2.12

EPS Est.

$2.09

Revenue

$15.50B

Beat/Miss

Beat by 1.4%

2025-11

EPS Actual

$2.38

EPS Est.

$2.28

Revenue

$15.19B

Beat/Miss

Beat by 4.4%

Urmatorul Raport

Data

2026-10-30

EPS Estimat

$2.64

Revenue Estimat

$16.05B

💰 Dividende Recente

2026-08

$1.06

Yield: 1.29%

Plata: 2026-09

2025-08

$0.515

Yield: 2.23%

Plata: 2025-09

2025-02

$1.05

Yield: 2.19%

Plata: 2025-03

2024-08

$0.5

Yield: 1.83%

Plata: 2024-09

📊 Scoruri Companie

Crestere 9/10

Revenue & Profit Growth

Evaluare 6/10

P/E · P/B · P/S

Calitate 9/10

Marje · ROE · Datorii

Risc 3/10

Beta · Market Cap

📈 Date Financiare Istorice in miliarde USD

💰 Revenue

📊 Net Profit

💵 Cash Flow

Operating (albastru) · Free (violet)

🏦 Cash & Datorii

Cash (verde) · Long-term Debt (rosu)

💸 Operating Expenses

🤖 Analiza RadarScope AI

Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.

💡 Disponibil pe Trader / Elite

🐂 BULL CASE

Disponibil pe Trader / Elite

🐻 BEAR CASE

Disponibil pe Trader / Elite

TINE Upgrade la Trader sau Elite pentru verdictul AI.

📖 Indicatorii lui Lynch — concluzii rapide dupa Peter Lynch

PEG — P/E in contextul cresterii

CORECT

PEG 1.14 · cu dividend 1.08 · crestere EPS ~21.8%/an. Regula Lynch: ~1 corect, sub 0.5 foarte atractiv, peste 2 scump.

P/E vs istoria proprie si sectorul

P/E acum 24.9.
vs media proprie 5 ani (320.5): SUB media sa
vs sector Healthcare (22.7): IN LINIE cu sectorul
Lynch: compara P/E cu propria istorie si media industriei, nu in absolut.

Procentul din vanzari (concentrare produs)

DIVERSIFICAT

Total Oncology 24% · CVRM 13% · Rare Disease 9% · Farxiga 8%
Lynch: un produs genial care aduce sub ~10% din venituri nu misca actiunea.

Cash si datorie

DATORIE NETA

Datorie neta pe actiune $14.29 (mai multa datorie decat cash).
Datorie/Capital 0.64 DATORIE MODERATA — decide supravietuirea in vremuri grele (esential la ciclice si turnarounds).
Tip datorie: OK — TERMEN LUNG — majoritar pe termen lung (obligatiuni = timp de manevra). Scurt $3.2B / Lung $24.7B.

Marje de profit

MARJE SOLIDE

Bruta 79.3% · Operationala 22.7% · Neta 17.0%. Marje mari — de regula castigatorul pe termen lung din industrie.

Inventare vs vanzari

ATENTIE

Stocurile cresc mai repede ca vanzarile (inventar +24% vs vanzari +9%) — semnal de alarma clasic.

Povestea in 2 minute

De ce o detii: Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.
Ce trebuie sa mearga bine: Disponibil pe Trader / Elite
Obstacole: Disponibil pe Trader / Elite
Lynch: daca nu poti explica coerent in 2 minute de ce o detii, nu o intelegi.

🔬 Analiza Fundamentala Avansata · an fiscal 2025-12-31

🏦 Altman Z-Score

3.41 ZONA SIGURA

X1 Capital de lucru / Active	-0.017	x1.2
X2 Profit reportat / Active	0.096	x1.4
X3 EBIT / Active	0.123	x3.3
X4 Capitalizare / Datorii	3.957	x0.6
X5 Vanzari / Active	0.515	x1.0

Praguri Altman (1968): >2,99 sigur · 1,81–2,99 gri · <1,81 pericol de faliment

💪 Piotroski F-Score

8/9 PUTERNIC

✓ROA pozitiv8.96%

✓Cash flow operational pozitiv14.57B

✓ROA in crestere8.96% vs 6.76%

✓Cash flow > Profit net (calitate)14.57B vs 10.22B

✓Datorie pe termen lung in scadere21.7% vs 25.5% din active

✓Lichiditate curenta in crestere0.94 vs 0.93

✓Fara emisiune de actiuni noi1550.8M vs 1550.1M

✓Marja bruta in crestere81.9% vs 81.1%

✗Rotatia activelor in crestere0.51 vs 0.52

9 teste binare (Piotroski, 2000). 8–9 = putere financiara · 0–2 = slabiciune

⚖️ ROIC vs WACC

+10.76pp CREEAZA VALOARE

ROIC (randamentul capitalului)	16.04%
WACC (costul capitalului)	5.28%

Ipoteze (la vedere):
Rata fara risc 4.2% (USD) · Beta 0.21 · Prima de risc 5.5%
Cost capitaluri proprii 5.36% · Cost datorie 5.54% · Impozit efectiv 17.5%

Metode publice: Altman, E. (1968), Journal of Finance · Piotroski, J. (2000), Journal of Accounting Research · ROIC/WACC prin CAPM. Fiecare cifra isi arata componentele si pragurile — poti reface calculul manual.

📊 Metrici Fundamentale

P/E TTM24.9

P/B TTM5.12

P/S TTM4.22

EV/EBITDA14.0

Gross Margin79.3%

Operating Margin22.7%

Net Margin17.0%

ROE21.7%

ROA9.0%

Debt/Equity0.64

Current Ratio0.89

FCF Yield3.3%

Dividend Yield1.28%

Beta0.21

💰 Venituri & Profit (ultimele trimestre)

Trimestru	Revenue	Gross Profit	Net Income	EPS
2026-06	$15.4B	$12.9B	$2.5B	$1.60
2026-03	$15.3B	$12.6B	$3.1B	$1.99
2025-12	$15.5B	$12.4B	$2.3B	$1.51
2025-09	$15.2B	$12.4B	$2.5B	$1.62

🏢 Profil Companie

CEOPascal Claude Roland Soriot

Angajati96100

IPO1993-05-12

Websitehttps://www.astrazeneca.com...

52W High$212.71

52W Low$145.80

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19...

🎯 Score Breakdown

Calitate Companie (Q) 9/10

Risc Speculativ (R) 3/10

Scor AI RadarScope 0/100

VERDICT FINAL

TINE

Upgrade la Trader sau Elite pentru verdictul AI.

🔒 Analiza completa disponibila cu cont SignalRadar